Nemes Rush Group
JAZZ icon

Nemes Rush Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Nemes Rush Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$232 Hold
1
– – ﹤0.01% 916
2026
Q2 		$241 Hold
1
– – ﹤0.01% 935
2026
Q1 		$189 Sell
1
-1
-50% -$175 ﹤0.01% 921
2025
Q4 		$340 Buy
+2
New +$307 ﹤0.01% 903

Other funds holding JAZZ

LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Nemes Rush Group's JAZZ Position: Q3 2026 in Review

Nemes Rush Group held its Jazz Pharmaceuticals (JAZZ) position steady in Q3 2026 at 1 share worth $232. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Nemes Rush Group first reported a position in JAZZ in Q4 2025 and has held it in 4 quarters since. The position peaked at $340 in Q4 2025. 331 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Nemes Rush Group held 1 share of Jazz Pharmaceuticals worth $232 as of Q3 2026.
  • Nemes Rush Group left its Jazz Pharmaceuticals share count unchanged in Q3 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #916 holding.
  • Nemes Rush Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Nemes Rush Group's Jazz Pharmaceuticals position peaked at $340 in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.